BioCanada

Found 34,478 articles

• Algernon Pharmaceuticals Receives Notice of Allowance from the Japanese Patent Office for Repirinast and the Treatment of CKD

  5/31/2023

  Algernon Pharmaceuticals Inc.  is pleased to announce that it has received a Notice of Allowance from the Japanese Patent Office (JPO) for patent application 2021-522114 entitled “Compositions and Methods for Treating Chronic Kidney Disease” for its lead chronic kidney disease (CKD) program drug NP-251.

• Kardium Announces First US Procedures in PULSAR Study of Globe® Pulsed Field System

  5/31/2023

  Kardium Inc., a private medical device company that has developed the Globe System for the treatment of atrial fibrillation (AF) using pulsed field ablation (PFA), announced today that the first US patients have been successfully treated in the PULSAR clinical study.

• IntelGenx Unveils Short-Term Commercial Objectives

  5/31/2023

  IntelGenx Corp. announced that it is executing on a plan focussed on near-term revenue generation.

• Brain Cancer Canada Awards St. Michael’s Hospital $100,000 Grant for Advanced DNA Sequencer Technology

  5/31/2023

  Brain Cancer Canada, the country’s leading charitable organization dedicated to brain cancer research, has announced a $100,000 grant to St. Michael’s Hospital, a site of Unity Health Toronto.

• Fusion Pharmaceuticals to Present at the 2023 Jefferies Healthcare Conference

  5/31/2023

  Fusion Pharmaceuticals Inc. announced that the Company will present in a fireside chat at the Jefferies Healthcare Conference on Wednesday, June 7, 2023 at 04:00 p.m. ET.

• Satellos Bioscience Announces 2023 Q1 Financial Results and Operational Highlights

  5/31/2023

  - $55 million equity financing closed - Resourced to advance lead drug candidate into clinical trials

• BioHarvest Reports Q1 2023 Results Demonstrating Strong Year Over Year Growth

  5/31/2023

  BioHarvest Sciences Inc. (CSE: BHSC) (OTCQB: CNVCF) (FSE: 8MV) ("BioHarvest" or "the Company") announces that it has released Q1 2023 results.

• BioMark Announces the U.S. Patent and Trademark Office Granted Patent with Claims Covering Its Lung Cancer Liquid Biopsy Assay

  5/31/2023

  The new family of patent granted by USPTO strengthens BioMark's global intellectual property position in liquid biopsy and early cancer detection

• Nanalysis to Present at LD Micro Invitational XIII

  5/31/2023

  Nanalysis Scientific Corp. announces that Chief Executive Officer, Sean Krakiwsky will be presenting at the 13th nnual LD Micro Invitational at the Luxe Sunset Boulevard Hotel, California on June 6th-8th, 2023.

• Aptose to Hold Interim Clinical Update Webcast on Saturday, June 10, 2023EHA Abstract on Tuspetinib and Venetoclax Recently Published

  5/31/2023

  Aptose Biosciences Inc. announced today that the company management team will provide a clinical update on Saturday, June 10, 2023, at 12:00 PM EST / 6:00 PM CEST.

• Xenon Pharmaceuticals to Present at the 2023 Jefferies Healthcare Conference

  5/31/2023

  Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present at the 2023 Jefferies Healthcare Conference taking place June 7-9, 2023 in New York, NY.

• Rakovina Therapeutics Inc. Announces Q1 2023 Financial Results and Provides Corporate Update

  5/31/2023

  Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company”), a biopharmaceutical company dedicated to improving the lives of cancer patients through development of novel DNA-damage response inhibitor therapeutics, announced financial results for the quarter ended March 31, 2023, and provided a corporate update.

• Triumvira Immunologics Highlights Positive Phase 1 Clinical Data on TAC01-HER2 in Solid Tumors at ASCO 2023 Annual Meeting

  5/31/2023

  Triumvira Immunologics today announced that positive data from its Phase I/II trial investigating the safety and efficacy of autologous TAC01-HER2 in refractory solid tumors (TACTIC-2/NCT04727151), will be presented at the 2023 American Society Of Clinical Oncology (ASCO) Annual Meeting.

• Alpha Cancer Technologies Presents New Data from ACT-903, an AFP-Maytansine Conjugate, in Online Publication at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

  5/31/2023

  Alpha Cancer Technologies Inc. (ACT) today announced details from the company’s abstract published as part of the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.

• Big Developments in Cancer Treatments set for Upcoming ASCO 2023 Annual Meeting in June

  5/31/2023

  USA News Group  -  With this year's Annual Meeting of the American Society of Clinical Oncology (ASCO 2023) less than 30 days away, there's plenty of anticipation for updates on some of the biggest developments in the world of cancer research.

• Profound Medical Announces Upcoming June 2023 Investor Events

  5/30/2023

  Profound Medical Corp., a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, announces the following investor events in June.

• Cubresa Installs First BrainPET Insert System at Lawson Health Research Institute

  5/30/2023

  Cubresa has installed the first BrainPET Insert System at St. Joseph’s Health Care London, in partnership with the hospital’s research institute – Lawson Health Research Institute.

• IPA's Subsidiary, BioStrand, Solves the Information Integration Dilemma (IID) for Systems Biology

  5/30/2023

  ImmunoPrecise Antibodies Ltd. announced that its subsidiary, BioStrand®, has successfully solved the Information Integration Dilemma by developing a unique technology design that enables their patented HYFT Technology to encapsulate and unify diverse data modalities - including syntactical data, 3D structural data, unstructured scientific information, and beyond - into a singular, integrated framework.

• Spectral Medical Provides Update on Favorable Tigris Clinical Trial Enrollment

  5/30/2023

  Spectral Medical Inc. today provided an enrollment update on Tigris, the Company’s follow-on study designed to build on knowledge gained from the earlier EUPHRATES trial.

• Rakovina Therapeutics Inc. Announces Closing of $1.5 Million Convertible Debenture Financing

  5/30/2023

  Rakovina Therapeutics Inc. is pleased to announce that it has closed its previously announced non-brokered private placement of unsecured convertible debenture units of the Company for aggregate gross proceeds to the Company of approximately $1.5 million.